Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- Drug Marketing Authorization Holders Submitted 36,641 Adverse Event Reports in FY2011: MHLW
August 14, 2012
- MHLW to Include Generic Drug Share Targets in Next 5-Year Medical Spending Optimization Plans in Response to Requests by Insurers
August 10, 2012
- MHLW Requires Revision of Package Inserts for 8 APIs including Oxaliplatin
August 9, 2012
- JPMA Calls for Maintenance and Expansion of R&D Tax Credit System at DPJ Hearings
August 9, 2012
- MHLW Study Group Takes Pass on Setting Up Relief System for Victims of Anticancer Drug Damage, Calling for Further Consideration by Government
August 8, 2012
- MOF Wants Generic Drug Share to Reach European, US Levels: Budget Examiner Shinkawa
August 8, 2012
- Talks between Health Minister, Plaintiff/Lawyer Groups Break Down on 3rd-Party Organization
August 7, 2012
- PAFSC’s First Committee Recommends Orphan Drug Designation for LAL Deficiency Treatment
August 7, 2012
- PAFSC’s First Committee Recommends Approval for Takeda’s Lotriga
August 7, 2012
- Health Minister Komiyama Continues Requesting IPV Price Cut
August 6, 2012
- DTP-IPV to Be Introduced in November; MHLW Anticipates Supply of 1.47 Million Doses by End of FY2012
August 6, 2012
- Ratio of Generics Rises 0.3 Points to 23.8%: Survey
August 3, 2012
- PMDA Determines Role of Science Board to Enhance Review System
August 2, 2012
- Council Generally Approves Revised Basic Policy for 2nd Med. Expenditure Optimization Plan; Regional Targets for Use of Generics to Be Included
August 2, 2012
- MHLW Investigative Commission Compiles Report to Improve Distribution of Novel Influenza Vaccines
August 1, 2012
- Council Approves Economic Revitalization Strategy with Priority on 3 Sectors Including Life Science
August 1, 2012
- MHLW to Issue Development Requests for 8 Drugs/Indications Determined to Have Unmet Medical Needs by Council on Unapproved Drugs
August 1, 2012
- MHLW Withdraws Development Request for Decitabine in Response to Approval for New Drug with Same Indication
August 1, 2012
- MHLW to Use Senshin-iryo System to Develop Anticancer Drugs from FY2013
July 30, 2012
- MHLW Approves Class 1 OTC Drugs for Allergic Rhinitis
July 30, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…